Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model.
B-cell chronic lymphocytic leukemia (CLL) remains an incurable disease, and despite the improvement achieved by therapeutic regimes developed over the last years still a subset of patients face a rather poor prognosis and will eventually relapse and become refractory to therapy. The natural rotenoid...
Main Authors: | Nerea Rebolleda, Ignacio Losada-Fernandez, Gema Perez-Chacon, Raquel Castejon, Silvia Rosado, Marta Morado, Maria Teresa Vallejo-Cremades, Andrea Martinez, Juan A Vargas-Nuñez, Paloma Perez-Aciego |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4839760?pdf=render |
Similar Items
-
Development of fludarabine formulations in the treatment of chronic lymphocytic leukemia
by: Ann Janssens, et al.
Published: (2009-10-01) -
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.
by: May Shawi, et al.
Published: (2013-01-01) -
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
by: S Walker, et al.
Published: (2009-06-01) -
T-cell large granular lymphocytic leukemia: treatment experience with fludarabine
by: Renata Oliveira Costa, et al.
Published: (2012-07-01) -
MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
by: Lupini Laura, et al.
Published: (2010-05-01)